story of the week
ESMO 2021: Benefits of Abiraterone Confirmed in Metastatic and High-Risk Nonmetastatic Prostate Cancer
Findings of STAMPEDE and PEACE-1 suggest abiraterone should be part of standard of care in both settings
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.